Login / Signup

Protecting children and adults with primary antibody deficiencies against common and emergent pathogens and non-infectious complications.

Olaf NethNizar MahlaouiCharlotte Cunningham-Rundles
Published in: Clinical and experimental immunology (2024)
Prevention and treatment of infections are primary goals of treatment of children and adults with primary immune deficiencies due to decreased antibody production. Approaches to these goals include immunoglobulin replacement therapy, vaccination, and prophylactic treatment with antimicrobials. In this review, the infectious and non-infectious complications of antibody deficiencies will be discussed along with the limited number of studies, that support the effective use of the available therapies and to drive the development of new therapies. Some illustrative case studies will be presented and the outlook for additional controlled clinical trials and potential for therapies driven by the underlying disease genetics will be considered.
Keyphrases
  • replacement therapy
  • clinical trial
  • young adults
  • randomized controlled trial
  • public health
  • combination therapy
  • risk assessment
  • open label
  • multidrug resistant
  • study protocol
  • human health